Intact MMAF-ADC ELISA kit
Monomethyl auristatin F (MMAF) is a potent synthetic antimitotic agent that inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis. In antibody–drug conjugates (ADCs), MMAF is linked to a monoclonal antibody that specifically targets tumor-associated antigens, allowing for selective delivery of the cytotoxic payload to cancer cells while minimizing systemic toxicity. Unlike its counterpart MMAE, MMAF is more hydrophilic and carries a charged phenylalanine residue, reducing its ability to cross cell membranes and thereby limiting bystander effects. “Intact MMAF ADC” refers to the fully conjugated and structurally complete antibody–drug complex, before intracellular cleavage and release of the active MMAF toxin.
Research and Clinical Applications:
In research settings, the quantification and characterization of intact MMAF ADCs serve as critical biomarkers for evaluating pharmacokinetics, stability, and bio-distribution. Analytical assays such as LC-MS/MS, ELISA, and hybrid immunoaffinity techniques are used to monitor the integrity of the ADC, drug-to-antibody ratio (DAR), and in vivo deconjugation rates. These biomarkers help optimize linker chemistry and dosing strategies during preclinical development. Clinically, intact MMAF ADC levels in patient plasma can provide insight into drug exposure, therapeutic response, and potential toxicity. Monitoring intact ADC concentration, along with total antibody and released payload levels, supports personalized dosing, efficacy assessment, and early detection of adverse effects, making it an essential component of translational pharmacology and biomarker-driven oncology research.
This Intact MMAF-ADC ELISA kit is manufactured in USA by Eagle Biosciences.
Related products
